News & Updates
Filter by Specialty:
Liver enzymes mediate association of particulate matter exposure with diabetes risk
Liver enzymes play a partial role in the relationship between exposure to particulate matter (PM) and risk of diabetes, indicating the involvement of lipid accumulation, oxidative stress, and chronic inflammation in the liver in its pathogenesis, reports a recent study.
Liver enzymes mediate association of particulate matter exposure with diabetes risk
19 Oct 2022
Lenvatinib-pembrolizumab combo fails to spring forward in HCC treatment
In the phase III LEAP*-002 study, a combination regimen comprising lenvatinib and pembrolizumab appeared to have similar efficacy and safety as lenvatinib monotherapy as first-line therapy for advanced hepatocellular carcinoma (HCC).
Lenvatinib-pembrolizumab combo fails to spring forward in HCC treatment
19 Oct 2022
Pre-DAA IL-1β can predict HBV reactivation in HCV
Among hepatitis C virus (HCV) patients with resolved hepatitis B virus (HBV) infections, levels of interleukin (IL)-1β before the initiation of direct-acting antiviral (DAA) treatment may help predict HBV reactivation, reports a recent study.
Pre-DAA IL-1β can predict HBV reactivation in HCV
14 Oct 2022
Carvedilol reduces decompensation, death in cirrhosis patients with hypertension
Long-term treatment with carvedilol lowers the risk of decompensation of cirrhosis and improves survival in compensated patients with clinically significant portal hypertension (CSPH), reports a study.
Carvedilol reduces decompensation, death in cirrhosis patients with hypertension
12 Oct 2022
Liver stiffness, but not fatty liver disease, linked to atrial fibrillation
Fatty liver disease does not seem to contribute to prevalent or incident atrial fibrillation (AF), but higher liver stiffness does, particularly among individuals without steatosis, reports a recent study.
Liver stiffness, but not fatty liver disease, linked to atrial fibrillation
11 Oct 2022
HBV elimination goals set by WHO not attainable, experts say
Current efforts to eradicate hepatitis B virus (HBV), including vaccination, screening, and treatment strategies, do not seem enough to achieve the elimination goals set by the World Health Organization (WHO), suggests a recent study.
HBV elimination goals set by WHO not attainable, experts say
11 Oct 2022
HBsAg seroclearance tied to lower recurrence risk of HBV-related hepatocellular carcinoma
Hepatitis B surface antigen (HBsAg) seroclearance appears to reduce the risk of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) late recurrence among patients who underwent curative liver resection, results of a Korea study have shown.
